0.26
-0.003(-1.14%)
Currency In USD
| Previous Close | 0.26 |
| Open | 0.27 |
| Day High | 0.27 |
| Day Low | 0.25 |
| 52-Week High | 1.73 |
| 52-Week Low | 0.22 |
| Volume | 130,516 |
| Average Volume | 1.15M |
| Market Cap | 4,662 |
| PE | -0.1 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.89 |
| Change | -0 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $0.82 as of January 22, 2026 at a share price of $0.261. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $4.44 as of January 22, 2026 at a share price of $0.261.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
GlobeNewswire Inc.
Jan 09, 2026 2:00 PM GMT
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a ne
Akari Therapeutics to Present at the 2026 Biotech Showcase
GlobeNewswire Inc.
Jan 08, 2026 2:15 PM GMT
In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GL
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
GlobeNewswire Inc.
Dec 30, 2025 2:15 PM GMT
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders fro